NCT06483308Active, not recruiting
Shortened High-dose Palliative Radiotherapy for Lung Cancer
Shortened High-dose Palliative Radiotherapy for Lung Cancer (SHiP-Rt) Study
Source: ClinicalTrials.gov · Last updated 26 Oct 2026
Brief summary (registry, in English)
The SHiP-Rt Study aims to investigate the safety and efficacy of reducing the number of RT fractions and RT duration, compared to the current standard of care (36Gy in 12 fractions over 16 days), by using shortened hypofractionated accelerated palliative radiotherapy (30Gy in 6 alternate-day fractions), aided by contemporary RT planning, verification, and delivery techniques.
- Status (registry)
- Active, not recruiting
- Study type
- Interventional
- Enrollment
- 37 (estimated)
- First submitted
- 17 Jun 2024
- Start date
- 27 Nov 2024
- Primary completion date
- 30 Jun 2026
- Lead sponsor
- University Hospitals Coventry and Warwickshire NHS Trust
- Diseases
- Lung cancer
- NCT number
- NCT06483308
What you commit to
- Study type: Interventional
- Planned participants: 37
- From 27 Nov 2024 to the primary completion date, 30 Jun 2026
- 4 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Requiring lung RT after second-line systemic therapy for NSCLC
- Previous radiotherapy to the same area
Other illness
- Has more than 1 cancer that is requiring active treatment
- On cytotoxic treatment for rheumatoid arthritis or connective tissue disorders
Other
- Contraindication for thoracic RT
- Poor life expectancy, likely less than 6 months
- Patients with difficulty regarding compliance to the study treatment or follow-up
Who the study is looking for
- Age ≥ 18
- Patient has locally advanced (stage IIIB or IIIC) or metastatic (stage IV) NSCLC
- Patient is treatment naïve or had limited progression after first-line systemic therapy (using chemotherapy, immunotherapy, or targeted therapy)
- Patient is suitable for high dose palliative RT (36Gy in 12# or 39Gy in 13#)
- Obtained written informed consent for the SHiP-Rt study.
- Patients receiving RT after first-line systemic therapy must have a wash-out period of at least 3 weeks (i.e., 3-4 weeks).
- Treatment naïve patients should be able to proceed to definitive systemic therapy without undue delay, i.e., within 3-4 weeks.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (4)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| University Hospitals Birmingham NHS Foundation Trust Coordinator of this site? Confirm its status | Birmingham | United Kingdom | Unknown status |
| University Hospitals Coventry and Warwickshire Coordinator of this site? Confirm its status | Coventry | United Kingdom | Unknown status |
| The Shrewsbury and Telford Hospital NHS Trust Coordinator of this site? Confirm its status | Shrewsbury | United Kingdom | Unknown status |
| University Hospitals of North Midlands NHS Trust Coordinator of this site? Confirm its status | Stoke-on-Trent | United Kingdom | Unknown status |
Related publications
This page is information, not medical advice. Discuss any trial with your doctor.